Back to top

Image: Bigstock

Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention

Read MoreHide Full Article

Did you analyze how Qiagen (QGEN - Free Report) fared in its international operations for the quarter ending June 2025? Given the widespread global presence of this diagnostic products maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.

In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.

Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.

While analyzing QGEN's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.

The company's total revenue for the quarter amounted to $533.54 million, marking an increase of 7.5% from the year-ago quarter. We will next turn our attention to dissecting QGEN's international revenue to get a clearer picture of how significant its operations are outside its main base.

Trends in QGEN's Revenue from International Markets

Of the total revenue, $73 million came from Asia Pacific, Japan and Rest of World during the last fiscal quarter, accounting for 13.7%. This represented a surprise of -5.37% as analysts had expected the region to contribute $77.14 million to the total revenue. In comparison, the region contributed $68.83 million, or 14.2%, and $76 million, or 15.3%, to total revenue in the previous and year-ago quarters, respectively.

Europe, Middle East and Africa generated $179 million in revenues for the company in the last quarter, constituting 33.6% of the total. This represented a surprise of +4.23% compared to the $171.73 million projected by Wall Street analysts. Comparatively, in the previous quarter, Europe, Middle East and Africa accounted for $160.64 million (33.2%), and in the year-ago quarter, it contributed $159 million (32%) to the total revenue.

Revenue Forecasts for the International Markets

The current fiscal quarter's total revenue for Qiagen, as projected by Wall Street analysts, is expected to reach $524.34 million, reflecting an increase of 4.5% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Asia Pacific, Japan and Rest of World is anticipated to contribute 14.3% or $74.92 million, and Europe, Middle East and Africa 32.3% or $169.29 million.

For the full year, a total revenue of $2.07 billion is expected for the company, reflecting an increase of 4.5% from the year before. The revenues from Asia Pacific, Japan and Rest of World and Europe, Middle East and Africa are expected to make up 14.4%, and 32.9% of this total, corresponding to $298.14 million, and $679.25 million, respectively.

In Conclusion

Qiagen's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In an era of growing international interdependencies and escalating geopolitical disputes, Wall Street analysts are vigilant in tracking these trends for businesses with a global reach, in order to refine their predictions of earnings. It should be noted, however, that a multitude of other elements, such as a company's domestic position, also play a significant role in shaping the earnings forecasts.

At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

Qiagen, bearing a Zacks Rank #3 (Hold), is expected to mirror the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Examining the Latest Trends in Qiagen's Stock Value

Over the preceding four weeks, the stock's value has diminished by 0.2%, against an upturn of 2.7% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Qiagen among its entities, has depreciated by 3.3%. Over the past three months, the company's shares have seen an increase of 12.6% versus the S&P 500's 13.2% increase. The sector overall has witnessed a decline of 1.8% over the same period.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


QIAGEN N.V. (QGEN) - free report >>

Published in